What's in a word? the person of personalized (nano)medicine

Nanomedicine

Volumn 10, Issue 20, 2015, Pages 3167-3179

  Guchet, Xavier ^a  

^a UNIVERSITÉ DE TECHNOLOGIE DE COMPIÈGNE   (France)

Author keywords

actionability biomarker; nanotechnology; personalization; spatialization

Indexed keywords

BIOMEDICINE; FOLLOW UP; GENETICS; HEALTH CARE POLICY; HUMAN; MEDICAL ETHICS; MEDICAL RESEARCH; MOLECULAR MEDICINE; NANOMEDICINE; NANOTECHNOLOGY; PERSONALIZED MEDICINE; PRIORITY JOURNAL; REVIEW; DRUG DELIVERY SYSTEM; PROCEDURES;

DRUG DELIVERY SYSTEMS; HUMANS; NANOTECHNOLOGY; PRECISION MEDICINE;

EID: 84944259419     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm.15.145     Document Type: Review

References (59)

1. Cullis P. The Personalized Medicine Revolution. How Diagnosing and Treating Disease Are About to Change Forever. Greystone Books, Vancouver, Canada (2015).
2. Rose N. Personalized medicine: promises, problems and perils of a new paradigm for healthcare. Procedia Soc. Behav. Sci. 77, 341-352 (2013).
3. Davis OK, Rosenwaks Z. Personalized medicine or one size fits all? Fertil Steril. 101(4), 922-923 (2014).
4. Pokorska-Bocci A, Stewart A, Sagoo GS et al. "Personalized Medicine": what's in a name? Pers. Med. 11(2), 197-210 (2014).
5. Cornetta K, Brown CG. Balancing personalized medicine and personalized care. Acad. Med. 88(3), 309-313 (2013).
6. Weston AD, Hood L. Systems biology, proteomics, and the future of health care: toward predictive, preventative and personalized medicine. J. Proteome Res. 3(2), 179-196 (2004).
7. Meyer UA. Pharmacogenetics. Five decades of therapeutic lessons from genetic diversity. Nat. Rev. Genet. 5, 669-676 (2004).
8. Table of pharmacogenomic biomarkers in drug labeling. www.fda.gov/Drugs/ScienceResearch/ResearchAreas
9. Paving the way for personalized medicine. FDA's role in the new era of medical product development. Report of the American Federal Food and Drug Administration (2013). www.fda.gov/downloads/scienceresearch/specialtopics
10. Dickenson D. Me Medicine vs We Medicine. Reclaiming Biotechnology for the Common Good. Columbia University Press, NY, USA (2013).
11. Morgan M. New paradigms in industry: the single nucleotide polymorphism consortium. In: The Role of Scientific and Technical Data and Information in the Public Domain: Proceedings of a Symposium. Esanu JM, Uhlir PF (Ed.). The National Academy Press, Washington, DC, USA (2003).
12. Rajan KS. Biocapital. The Construction of Postgenomic Life. Duke University Press, Duham, London, UK (2006).
13. Langreth R, Waldholz M. New era of personalized medicine. targeting drugs for each unique genetic profile. Oncologist 4(5), 426-427 (1999).
14. Gibson WM. Can personalized medicine survive? Can. Fam. Phys. 17(8), 29-88 (1971).
15. Motulsky A. Drug reactions, enzymes and biochemical genetics. JAMA 165, 835-837 (1957).
16. Kalow W. Phamacogenetics, Heredity and the Response to Drugs. WB Saunders Co, PA, USA (1962).
17. Cambrosio A, Keating P. Cancer on Trial: Oncology as a New Style of Practice. University of Chicago Press, IL, USA (2012).
18. Dondorp WJ, de Wert G. The 'thousand-dollar genome': an ethical exploration. Eur. J. Hum. Genet. 21, 6-26 (2013).
19. Zhu Z, Cuozzo J. Review article: high-throughput affinitybased technologies for small-molecule drug discovery. J. Biomol. Screen. 14(10), 1157-1164 (2009).
20. Nomura DK, Dix MM, Cravatt BF. Activity-based protein profiling for biochemical pathway discovery in cancer. Nat. Rev. Cancer 10(9), 630-638 (2010).
21. Jain KK. Nanobiotechnology and personalized medicine. Prog. Mol. Biol. Transl. Sci. 104, 325-354 (2011).
22. Wang WU, Chen C, Lin KH et al. Label-free detection of small-molecule-protein interactions by using nanowire nanosensors. Proc. Natl Acad. Sci. USA 102(9), 3208-3212 (2005).
23. Nune SK, Gunda P, Thallapally PK. Nanoparticles for biomedical imaging. Expert Opin. Drug Deliv. 6(11), 1175-1194 (2009).
24. Kim TH, Lee S, Chen X. Nanotheranostics for personalized medicine. Expert. Rev. Mol. Diagn. 13(3), 257-269 (2013).
25. Niculescu-Duvaz I. Trastuzumab emtansine, an antibodydrug conjugate for the treatment of HER2+ metastatic breast cancer. Curr. Opin. Mol. Ther. 12(3), 350-360 (2010).
26. Cau JC, Lalo H, Séverac C et al. Molecular analysis for medicine: a new technological platform based on nanopatterning and label-free optical detection. Oncology 11, S148-S152 (2009).
27. Wanunu M. Nanopores: A journey toward DNA sequencing. Phys. Life Rev. 9, 125-158 (2012).
28. Chalmeau J, Monina N, Shin J et al. ?-Hemolysin pore formation into a supported phospholipid bilayer using cellfree expression. Biochim. Biophys. Acta 1808(1), 271-278 (2010).
29. Foucault M. The Birth of the Clinic. An Archaeology of Medical Perception. Tavistock Publications Limited, London, UK (1973).
30. The case for personalized medicine. Report of the Personalized Medicine Coalition (2011). www.personalizedmedicinecoalition.org/Userfiles/PMC
31. Médecine Personnaliseé et Cancer. Organiser et Financer l'Accès à l'Innovation. Paci A (Ed.). Presses de l'Institut Gustave Roussy, Villejuif, France, 16 (2013)
32. EMIR study (European Area). Effets indésirables des médicaments: incidence et risque. www.sante.gouv.fr/IMG/pdf/EMIR.pdf
33. Arrosmith J. A decade of change. Nat. Rev. Drug Discov. 11, 17-18 (2012).
34. Ormond KE, Cho MK. Translating personalized medicine using new genetic technologies in clinical practice: the ethical issues. Pers. Med. 11(2), 211-222 (2014).
35. Soden SE, Farrow EG, Saunders CJ et al. Genomic medicine: evolving science, evolving ethics. Pers. Med. 9(5), 523-528 (2012).
36. McGuire AL, Lupski JR. Personal genome research: what should the participant be told? Trends Genet. 26(5), 199-201 (2010).
37. Feldman EA. The Genetic Information Nondiscrimination Act (GINA): public policy and medical practice in the age of personalized.medicine J. Gen. Intern. Med. 27(6), 743-746 (2011)
38. Chadwick R, O'Connor A. Epigenetics and personalized medicine: prospects and ethical issues. Pers. Med. 10(5), 463-471 (2013).
39. Rose N. The Politics of Life Itself. Biomedicine, Power, and Subjectivity in the Twenty-First Century. Princeton University Press, Princeton & Oxford, USA (2007).
40. Kahn J. Race in a Bottle: The Story of BiDil and Racialized Medicine in a Post-genomic Age. Columbia University Press, NY, USA (2013).
41. Fleck LM. Pharmacogenomics and personalized medicine: wicked problems, ragged edges and ethical precipices. New Biotechnol. 29(6), 757-768 (2012).
42. Fleck LM. Just caring: assessing the ethical and economic costs of personalized medicine. Urol. Oncol. 32(2), 202-206 (2014).
43. Gray SW, Hicks-Courant K, Lathan CS et al. Attitudes of patients with cancer about personalized medicine and somatic genetic testing. J. Oncol. Pract. 8(6), 329-335 (2012).
44. Mezzich JE. Person-centred integrative diagnosis: conceptual bases and structural model. Can. J. Psychiatry 55(11), 701-708 (2010).
45. Balint E. The possibilities of patient-centered medicine. J. R. Coll. Gen. Pract. 17, 269-276 (1969).
46. Mead N, Bower P. Patient-centredness: a conceptual framework and review of the empirical literature. Soc. Sci. Med. 51, 1087-1110 (2000).
47. Ekman I, Swedberg K, Taft C et al. Person-centered care-ready for prime time. Eur. J. Cardiovasc. Nurs. 10(4), 248-251 (2011).
48. Engel GL. The need for a new medical model: a challenge for biomedicine. Science 196(4286), 129-136 (1977).
49. André F, Delaloge S, Soria JC. Biology-driven Phase I trial: what is the optimal model for molecular selection? J. Clin. Oncol. 29(10), 1236-1238 (2011).
50. Tursz T, André F, Lazar V et al. Implications of personalized medicine-perspective from a cancer center. Nat. Rev. Clin. Oncol. 8, 177-183 (2011).
51. Boenink M. Molecular medicine and concepts of disease: the ethical value of a conceptual analysis of emerging biomedical technologies. Med. Health Care Philos. 13(1), 11-23 (2010).
52. Gion M, Trevisiol C, Pregno S et al. Guida all'uso clinico dei biomarcatori in oncologia: la prospettive. Biochim. Clin. 36(1), 40-45 (2012).
53. Pepe MS, Janes H, Longton G et al. Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic, or screening marker. Am. J. Epidemiol. 159(9), 882-890 (2004).
54. Barabási AL, Gulbahce N, Loscalzo J. Network medicine: a Network-Based Approach to Human Disease. Nat. Rev. Genet. 12(1), 56-68 (2011)
55. Hedgecoe A. The Politics of Personalized Medicine: Pharmacogenetics in the Clinic. Cambridge University Press, MA, USA, 99 (2005).
56. Nelson NC, Keating P, Cambrosio A. On being "Actionable": clinical sequencing and the emerging contours of a regime of genomic medicine in oncology. New Genet. Soc. 32(4), 405-428 (2013).
57. Wild CP. Complementing the genome with an "Exposome": the oustanding challenge of environmental exposure measurement in molecular epidemiology. Cancer Epidemiol. Biomarkers Prev. 14, 1847-1850 (2005).
58. Exposome and exposomics. www.cdc.gov/niosh/topics/exposome
59. Canguilhem G. The Normal and the Pathological. Zone Books, NY, USA (1991).